Colorectal Cancer News and Research

Latest Colorectal Cancer News and Research

Merrimack acquires development and commercialization rights to MM-398 in Europe, Asia

Merrimack Pharmaceuticals, Inc. and PharmaEngine, Inc. today announced the signing of an agreement under which Merrimack has acquired the rights to develop and commercialize MM-398 in Europe and Asia.

9 May 2011

Epigenomics, Life Technologies enter supply agreement for second-generation colorectal cancer blood test

Epigenomics AG, the cancer molecular diagnosis company, today announced the signing of a supply agreement with Life Technologies Corporation, a global provider of innovative life science solutions.

7 May 2011

Research roundup: Racial disparities in cancer screening and VA treatment

Racial And Ethnic Disparities In Colorectal Cancer Screening Persisted Despite Expansion Of Medicare's Screening Reimbursement. This study looked at the effect in minority groups of expanded reimbursements by Medicare for colorectal cancer screenings.

7 May 2011

DiagnoCure to showcase Previstage GCC Colorectal Cancer Staging Test at ASCRS meeting

DiagnoCure, Inc., a life sciences company commercializing high‐value cancer diagnostic tests and delivering laboratory services, today reported that its PrevistageTM GCC Colorectal Cancer Staging Test will be featured at the annual meeting of the American Society of Colon and Rectal Surgeons to be held in Vancouver, Canada, from May 15 to 17, 2011, with 3,000 expected attendees.

6 May 2011

Despite expanded Medicare coverage racial disparities continue in colorectal cancer screening

Despite expanded Medicare coverage for colorectal cancer screening tests, lower rates still exist among blacks and Hispanics compared to other ethnic groups, according to research published in Cancer, Epidemiology, Biomarkers & Prevention, a journal of the American Association for Cancer Research.

6 May 2011

ArQule reports net loss of $1,466,000 for first quarter 2011

ArQule, Inc. today announced its financial results for the first quarter of 2011.

5 May 2011

Alcohol and raised cancer risk: Report

These numbers come from the Cancer Council analysis that reveals the number of cancer cases caused by long-term drinking in Australia is far higher than previously thought, following strong international evidence of its link to a broader range of cancer types.

1 May 2011

Extensive folic acid fortification of foods prevents neural tube defects in neonates

Neural tube defects in neonates are common in Germany compared with the rest of Europe. Extensive folic acid fortification of foods in Germany might prevent these in 85-100% of cases, Wolfgang Herrmann and Rima Obeid argue in this issue of Deutsches Ärzteblatt International (Dtsch Arztebl Int 2011; 108[15]; 249-54).

30 Apr 2011

Keryx Biopharmaceuticals reports net loss of $6.4 million for first quarter 2011

Keryx Biopharmaceuticals, Inc., a biopharmaceutical company focused on the acquisition, development and commercialization of medically important pharmaceutical products for the treatment of cancer and renal disease, today announced its results for the first quarter ended March 31, 2011.

30 Apr 2011

Spectrum receives FDA approval for FUSILEV to treat colorectal cancer

Spectrum Pharmaceuticals, a biotechnology company with fully integrated commercial and drug development operations with a primary focus in oncology, received approval from the U.S. Food and Drug Administration on April 29, 2011, for the use of FUSILEV in combination with 5-fluorouracil in the palliative treatment of patients with advanced metastatic colorectal cancer.

30 Apr 2011

New device can reduce pain during colon cancer screening

Colonoscopy is regarded as the most thorough way to screen for colon cancer but the potentially life-saving procedure can also be painful.

28 Apr 2011

CTNNB1 activation can improve colorectal cancer survival in obese patients

Among obese patients, activation of the protein biomarker CTNNB1 was associated with better colorectal cancer-specific survival and overall survival, whereas post-diagnosis physical activity was associated with better colorectal cancer-specific survival among patients negative for CTNNB1, according to a study in the April 27 issue of JAMA.

27 Apr 2011

Brain-derived protein in colorectal cancer

Tumor progression is usually ensured by more than one proliferative mechanism. When one of these is shut down by a specifically targeted drug, other mechanisms may emerge. While these events may lead to treatment failure, they may also become an opportunity for researchers to identify novel targets to be further explored.

27 Apr 2011

Positive results from Sanofi-aventis and Regeneron ZALTRAP Phase III study in mCRC

Sanofi-aventis and Regeneron Pharmaceuticals, Inc. announced that the Phase III VELOUR trial evaluating the investigational agent ZALTRAP, also known as VEGF Trap, in combination with the FOLFIRI chemotherapy regimen versus a regimen of FOLFIRI plus placebo met its primary endpoint of improving overall survival in the second-line treatment of metastatic colorectal cancer.

27 Apr 2011

Colorectal cancer patients with genetic mutation can benefit from new class of drugs

A class of drugs that shows promise in breast and ovarian cancers with BRCA gene mutations could potentially benefit colorectal cancer patients with a different genetic mutation, a new study from the University of Michigan Comprehensive Cancer Center finds.

26 Apr 2011

Study: 80% of blacks more likely to spend all personal finances for cancer care

People in minority groups, especially black Americans, are more willing than their white counterparts to exhaust their personal financial resources to prolong life after being diagnosed with lung or colorectal cancer, according to a University of Alabama at Birmingham study published April 26, 2011, online in Cancer, the journal of the American Cancer Society.

26 Apr 2011

Analysis of the health law's effects continues

Reports look at the diverse effects of the health law — from Medicare and Medicaid to the accountable care organizations.

25 Apr 2011

FDA approves Spectrum's FUSILEV Injection to treat metastatic colorectal cancer

Spectrum Pharmaceuticals, a biotechnology company with fully integrated commercial and drug development operations with a primary focus in oncology, today announced that the U.S. Food and Drug Administration has approved the Company's Supplemental New Drug Application for FUSILEV Injection.

22 Apr 2011

Nature solves complex topological puzzles in DNA substrate recognition with elegant simplicity

A major discovery about an enzyme's structure has opened a window on understanding DNA repair. Scientists at Duke University Medical Center have determined the structure of a nuclease that will help scientists to understand several DNA repair pathways, a welcome development for cancer research.

21 Apr 2011

Ludwig Institute demonstrates ability of DAVANAT to enhance efficacy of T-lymphocytes to kill tumor cells

Pro-Pharmaceuticals, Inc. today announced that the Brussels Branch of the Ludwig Institute for Cancer Research demonstrated the ability of GM-CT-01 (DAVANAT®) to enhance the ability of tumor-specific T-lymphocytes to kill tumor cells.

20 Apr 2011

Colorectal Cancer News and Research

Latest Colorectal Cancer News and Research

Merrimack acquires development and commercialization rights to MM-398 in Europe, Asia

Epigenomics, Life Technologies enter supply agreement for second-generation colorectal cancer blood test

Research roundup: Racial disparities in cancer screening and VA treatment

DiagnoCure to showcase Previstage GCC Colorectal Cancer Staging Test at ASCRS meeting

Despite expanded Medicare coverage racial disparities continue in colorectal cancer screening

ArQule reports net loss of $1,466,000 for first quarter 2011

Alcohol and raised cancer risk: Report

Extensive folic acid fortification of foods prevents neural tube defects in neonates

Keryx Biopharmaceuticals reports net loss of $6.4 million for first quarter 2011

Spectrum receives FDA approval for FUSILEV to treat colorectal cancer

New device can reduce pain during colon cancer screening

CTNNB1 activation can improve colorectal cancer survival in obese patients

Brain-derived protein in colorectal cancer

Positive results from Sanofi-aventis and Regeneron ZALTRAP Phase III study in mCRC

Colorectal cancer patients with genetic mutation can benefit from new class of drugs

Study: 80% of blacks more likely to spend all personal finances for cancer care

Analysis of the health law's effects continues

FDA approves Spectrum's FUSILEV Injection to treat metastatic colorectal cancer

Nature solves complex topological puzzles in DNA substrate recognition with elegant simplicity

Ludwig Institute demonstrates ability of DAVANAT to enhance efficacy of T-lymphocytes to kill tumor cells

CellVoyant's AI-Powered Vision for the Future of Cell Therapy

Scalable, Smart, and Accessible: The Future of Lab Automation

Healthy Beginnings, Hopeful Futures: A Conversation with WHO’s Dr. Allotey

Colorectal Cancer News and Research

Latest Colorectal Cancer News and Research

CellVoyant's AI-Powered Vision for the Future of Cell Therapy

Scalable, Smart, and Accessible: The Future of Lab Automation

Healthy Beginnings, Hopeful Futures: A Conversation with WHO’s Dr. Allotey

Newsletters you may be interested in